Literature DB >> 34548196

Lung transplantation disparities based on diagnosis for patients bridging to transplant on extracorporeal membrane oxygenation.

David Furfaro1, Erika B Rosenzweig2, Lori Shah3, Hilary Robbins3, Michaela Anderson3, Hanyoung Kim3, Darryl Abrams3, Cara L Agerstrand3, Daniel Brodie3, Danielle Feldhaus4, Joseph Costa4, Philippe Lemaitre4, Bryan P Stanifer4, Frank D'Ovidio4, Joshua R Sonett4, Selim Arcasoy3, Luke Benvenuto3.   

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is increasingly utilized as a bridge to lung transplantation, but ECMO status is not explicitly accounted for in the Lung Allocation Score (LAS). We hypothesized that among waitlist patients on ECMO, patients with pulmonary arterial hypertension (PAH) would have lower transplantation rates.
METHODS: Using United Network for Organ Sharing data, we conducted a retrospective cohort study of patients who were ≥12 years old, active on the lung transplant waitlist, and required ECMO support from June 1, 2015 through June 12, 2020. Multivariable competing risk analysis was used to examine waitlist outcomes.
RESULTS: 1064 waitlist subjects required ECMO support; 40 (3.8%) had obstructive lung disease (OLD), 97 (9.1%) had PAH,138 (13.0%) had cystic fibrosis (CF), and 789 (74.1%) had interstitial lung disease (ILD). Ultimately, 671 (63.1%) underwent transplant, while 334 (31.4%) died or were delisted. The transplant rate per person-years on the waitlist on ECMO was 15.41 for OLD, 6.05 for PAH, 15.66 for CF, and 15.62 for ILD. Compared to PAH patients, OLD, CF, and ILD patients were 78%, 69%, and 62% more likely to undergo transplant throughout the study period, respectively (adjusted SHRs 1.78 p = 0.007, 1.69 p = 0.002, and 1.62 p = 0.001). The median LAS at waitlist removal for transplantation, death, or delisting were 75.1 for OLD, 79.6 for PAH, 91.0 for CF, and 88.3 for ILD (p < 0.001).
CONCLUSIONS: Among patients bridging to transplant on ECMO, patients with PAH had a lower transplantation rate than patients with OLD, CF, and ILD.
Copyright © 2021 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ECMO; advanced lung disease; lung allocation score; lung transplant; pulmonary hypertension

Mesh:

Year:  2021        PMID: 34548196      PMCID: PMC9284417          DOI: 10.1016/j.healun.2021.08.005

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   13.569


  25 in total

1.  Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry.

Authors:  Raymond L Benza; Dave P Miller; Adaani Frost; Robyn J Barst; Abby M Krichman; Michael D McGoon
Journal:  Transplantation       Date:  2010-08-15       Impact factor: 4.939

2.  OPTN/SRTR 2013 Annual Data Report: lung.

Authors:  M Valapour; M A Skeans; B M Heubner; J M Smith; M I Hertz; L B Edwards; W S Cherikh; E R Callahan; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2015-01       Impact factor: 8.086

3.  Characteristics of lung allocation score exception requests submitted to the national Lung Review Board.

Authors:  Keith M Wille; Leah B Edwards; Liz Robbins Callahan; Aaron R McKoy; Kevin M Chan
Journal:  J Heart Lung Transplant       Date:  2017-03-06       Impact factor: 10.247

4.  Lung Transplant Mortality Is Improving in Recipients With a Lung Allocation Score in the Upper Quartile.

Authors:  Todd C Crawford; Joshua C Grimm; J Trent Magruder; Jinny Ha; Christopher M Sciortino; Bo S Kim; Errol L Bush; John V Conte; Robert S Higgins; Ashish S Shah; Christian A Merlo
Journal:  Ann Thorac Surg       Date:  2017-02-21       Impact factor: 4.330

5.  Effect of the lung allocation score on lung transplantation in the United States.

Authors:  Thomas M Egan; Leah B Edwards
Journal:  J Heart Lung Transplant       Date:  2016-01-15       Impact factor: 10.247

6.  Survival in pulmonary arterial hypertension patients awaiting lung transplantation.

Authors:  Mardi Gomberg-Maitland; Cherylanne Glassner-Kolmin; Sydeaka Watson; Robert Frantz; Myung Park; Adaani Frost; Raymond L Benza; Fernando Torres
Journal:  J Heart Lung Transplant       Date:  2013-09-25       Impact factor: 10.247

7.  Update on pediatric lung allocation in the United States.

Authors:  Stuart C Sweet
Journal:  Pediatr Transplant       Date:  2009-11

8.  Extracorporeal membrane oxygenation as a novel bridging strategy for acute right heart failure in group 1 pulmonary arterial hypertension.

Authors:  Erika B Rosenzweig; Daniel Brodie; Darryl C Abrams; Cara L Agerstrand; Matthew Bacchetta
Journal:  ASAIO J       Date:  2014 Jan-Feb       Impact factor: 2.872

9.  Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals.

Authors:  David J Lederer; Scott C Bell; Richard D Branson; James D Chalmers; Rachel Marshall; David M Maslove; David E Ost; Naresh M Punjabi; Michael Schatz; Alan R Smyth; Paul W Stewart; Samy Suissa; Alex A Adjei; Cezmi A Akdis; Élie Azoulay; Jan Bakker; Zuhair K Ballas; Philip G Bardin; Esther Barreiro; Rinaldo Bellomo; Jonathan A Bernstein; Vito Brusasco; Timothy G Buchman; Sudhansu Chokroverty; Nancy A Collop; James D Crapo; Dominic A Fitzgerald; Lauren Hale; Nicholas Hart; Felix J Herth; Theodore J Iwashyna; Gisli Jenkins; Martin Kolb; Guy B Marks; Peter Mazzone; J Randall Moorman; Thomas M Murphy; Terry L Noah; Paul Reynolds; Dieter Riemann; Richard E Russell; Aziz Sheikh; Giovanni Sotgiu; Erik R Swenson; Rhonda Szczesniak; Ronald Szymusiak; Jean-Louis Teboul; Jean-Louis Vincent
Journal:  Ann Am Thorac Soc       Date:  2019-01

10.  Lung Transplantation in Patients with High Lung Allocation Scores in the US: Evidence for the Need to Evaluate Score Specific Outcomes.

Authors:  Jeremiah A Hayanga; Alena Lira; Tedi Vlahu; Jingyan Yang; Jonathan K Aboagye; Heather K Hayanga; James D Luketich; Jonathan D'Cunha
Journal:  J Transplant       Date:  2015-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.